Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

  • Verkindre C
  • Fukuchi Y
  • Flémale A
 et al. 
  • 50


    Mendeley users who have this article in their library.
  • 63


    Citations of this article.


NVA237 is a once-daily inhaled long-acting muscarinic antagonist in development for the treatment of COPD. This randomized, double-blind, placebo-controlled, four-period, incomplete block crossover study, with open-label active comparator (tiotropium), assessed the efficacy and safety of NVA237. Patients (≥40 years; smoking history ≥10 pack-years) with stable moderate-to-severe COPD (post-bronchodilator FEV1≥ 30% and

Author-supplied keywords

  • COPD
  • Efficacy
  • Long-acting muscarinic antagonist
  • NVA237
  • Safety
  • Tiotropium

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free